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Despite dramatic increases in the survival of cancer in general over the last 5 decades, the 
5-year survival of pancreatic ductal adenocarcinoma (PDAC) remains relatively unchanged at 
6%. Approximately 10% of PDAC cases are familial pancreatic cancer (FPC), involving two or 
more affected first-degree relatives. Despite large sequencing efforts over the past decade, less 
than 20% of FPC cases have an identified causal germline mutation, despite recent large-scale 
sequencing efforts by our group and others.  
Unlike the majority of familial cancer syndromes, our analysis shows that FPC is not 
associated with an earlier age of onset compared to its sporadic counterpart. We theorized that the 
similar age of onset may be the result of shared between sporadic and familial PDAC driver 
genes, KRAS, TP53, CDKN2A/p16, and DPC4/SMAD4. Our analysis of PDAC driver genes in 
our cohort of FPC cancer cell lines, using high density SNP microarray, whole exome sequencing 
(WES), whole genome sequencing (WGS), and RNA-Seq, confirmed that FPC has alterations in 
the PDAC driver genes and at the same prevalence as sporadic.  
Given that the genes p16 and SMAD4 are commonly inactivated by deletions, we 
hypothesized that the underlying structural rearrangements could provide insight into the 
mechanism of driver gene deletions in cancer. Our breakpoint analysis of the p16 and SMAD4 
deletions using WGS data revealed a novel structural variant that we have termed “TransFlip 
mutations.” A TransFlip mutation is an inter-chromosomal translocation on one side and an 
inversion on the other side, flanking a deletion. 
My thesis work highlights the similarity of FPC with sporadic PDAC, both in the driver 
genes and in the age of onset. Here I report the discovery of TransFlip mutations, a new structural 
variant in cancer, highlighting the complexity of cancer genomes and the challenges of reliably 




Dr. James R. Eshleman (Reader) 
 
Thesis Committee: 
Dr. Sarah J. Wheelan (Reader) 
Dr. Kenneth W. Kinzler (Chair) 
Dr. Ralph H. Hruban 






I would first like to thank my mentor Dr. James Eshleman, for having faith in my ability 
to be an independent scientist from day one. He has been supportive, encouraging, and 
inspirational throughout my time here, and allowed me the freedom to pursue research that 
excites me. My thesis committee members Drs. Kenneth Kinzler, Ralph Hruban, Alison Klein, 
and Sarah Wheelan provided critical input to my thesis project, and I appreciate all their time and 
efforts. I also thank my lab members and the larger G.I. Pathology group for their technical 
advice and support. Specifically, I would like to thank Dr. Niki Ottenhof, whose friendship and 
support has never wavered, even now from across the Atlantic Ocean. 
I thank my undergraduate mentors Drs. Carol Ely-Hepfer and Richard Bamford for 
teaching me how to use a pipette and pushing me to pursue academic research. Then as a 
technician at Johns Hopkins, it was my mentors Drs. Kathleen Murphy and Constance Griffin 
who provided an opportunity for research that led to my first publications. I deeply thank both of 
them, as well as all of my colleagues, past and present, at the Molecular Diagnostics Lab.  
Once I began the Cellular and Molecular Medicine (CMM) graduate program, Dr. Rajini 
Rao, Colleen Graham, and Leslie Lichter became my support team, and I am grateful for their 
help getting me through those first years. My CMM classmates became my new family during 
those long days and nights studying for our qualifying exam. A special thanks to my classmates 
Allie Galanis (Western Blot expert), Sean Cho (R expert), Aggie Rucki (mouse expert), and Nina 
Hosmane (cell culture expert), for both their scientific advice and friendship.  
Thank you Dr. Benjamin Orsburn for reminding me every day how much I love science, 
pugs, and you. Finally, I would like to thank my family, including my grandfather Dr. Vincent 
Norris, for everything you have done for me throughout the years. From an early age, you 
fostered my scientific curiosity and urged me to pursue a career that I love.  
v 
 
TABLE OF CONTENTS 
ABSTRACT ……………………………………………...…….……….………………….…… ii 
ACKNOWLEDGEMENTS ……………………………………….….……..……...…….…… iv 
TABLE OF CONTENTS ……………………………………..…………………….……..…… v 
LIST OF TABLES …………………………………………..………..……………..…...….… vi 
LIST OF FIGURES ………………………..………..…...……………..……….……....……. viii 
CHAPTER 1: Introduction …………...……….……………………………………....…..…..… 1 
CHAPTER 2: Familial and sporadic pancreatic cancer share the same molecular 
pathogenesis………..……..…………………………………………………………..…….…….. 5 
CHAPTER 3: Discovery of TransFlip mutations of p16 and SMAD4 pancreatic cancer tumor 
suppressor genes ………..……..………….…………………………………….…………...….. 29 
CHAPTER 4: Challenges in discovering familial pancreatic cancer predisposition genes ….... 63 
CHAPTER 5: Significance and future directions …………………………….....……..…….… 76 
REFERENCES ……………………………………...…………..………………….…....…..… 79 




LIST OF TABLES 
Table 1.1 ………………………………….…………...…………………....……….……..…..… 4 
Known FPC predisposition genes 
Table 2.1 ………………………………….…………...………………….…...…..….…..…..… 21 
FPC cohort demographics 
Table 2.2 ………………………………….…………...………………….…...……...…..…..… 22 
Relative power of each method to detect common alterations 
Supplemental Table 2.1 ……………….…………...………………….………..…..……….… 23 
Summary of the literature collated for age of onset analysis  
Supplemental Table 2.2 ……………….…………...………………….……..…..……..…...… 24 
Age of onset in our SPC and FPC cohorts 
Supplemental Table 2.3 ……………….…………...………………….………….……..…..… 25 
KRAS mutation spectrum in FPC vs. SPC 
Supplemental Table 2.4 ……………….…………....………………….….……...……..…..… 26 
CDKN2A/p16 mutation spectrum in FPC vs. SPC 
Supplemental Table 2.5 ……………….…………...………….………….……….….....…..… 27 
TP53 mutation spectrum in FPC vs. SPC 
Supplemental Table 2.6 ……………….…………...…………...………….………..…..…..… 28 
SMAD4/DPC4 mutation spectrum in FPC vs. SPC 
Table 3.1 ………………………………….…………...………………….…...……...…..…..… 47 
Summary of p16 and SMAD4 deletions  
vii 
 
Table 3.2 ………………………………….…………...………………….…...……...…..…..… 48 
Structural variants that underlie p16 and SMAD4 deletions 
Table 3.3 ………………………………….…………...………………….…...……...…..…..… 49 
Characteristics of TransFlip mutations  
Supplemental Table 3.1 ……………….…………...………………….………..…..……….… 53 
Characteristics of known SV mechanisms  
Supplemental Table 3.2 ……………….…………...………………….………..…..……….… 54 
Summary somatic HDs, by sample and by SV type  
Supplemental Table 3.3 ……………….…………...………………….………..…..……….… 55 
Details of all somatic HDs  
Supplemental Table 3.4 ……………….…………...………………….………..…..……….… 59 
p16 and SMAD4 deletions details  
Supplemental Table 3.5 ……………….…………...………………….………..…..……….… 60 
Patient and cell line characteristics  
Supplemental Table 3.6 ……………….…………...………………….………..…..……….… 61 
Breakpoint characteristics of p16 and SMAD4 deletions  
Table 4.1 ……………………………………………....…………….....…….……….…..…..… 74 
Value of an integrated approach  
Table 4.2 ……………………………………………....…………….....…….……….…..…..… 75 
Germline intragenic HDs in FPC samples and normal controls (CIDR)  
viii 
 
LIST OF FIGURES 
Figure 2.1 ………………………………………...………….………...….……….……..…..… 18 
Reported age of onset for sporadic PDAC and FPC, collated from the literature  
Figure 2.2 ………………………………………...………….………….…….…..……..…...… 19 
Summarized alterations in PDAC molecular progression genes, for Sporadic PDAC and FPC  
Figure 2.3 ………………………………………...………….…………….….…..……...…..… 20 
CDKN2A/p16 homozygous deletion (HD) initially missed by WGS 
Figure 3.1 ………………………………………...………….………….…….…….……..…… 42 
Signature of a HD in IGV       
Figure 3.2 ………………………………………...………….………….…………..……..…… 43 
Most somatic HDs are simple interstitial deletions, but TransFlip mutations more prevalent in   
p16 and SMAD4 deletions  
Figure 3.3 ………………………………………...………….………….……….….…....…..… 44 
Derivative chromosomes of p16 and SMAD4 deletions 
Figure 3.4 ………………………………………...………….………….…….…….………..… 45 
Fold-back inversion seen in one TransFlip mutation 
Figure 3.5 ………………………………………...………….………….…….…….………..… 46 
Proposed sequential mechanisms for TransFlip mutations 
Supplemental Figure 3.1 ………………………………...………….….…….…….……..…… 50 
Complexity of TransFlip in IGV 
Supplemental Figure 3.2 ………………………………...………….….…….…….……..…… 52 
Chromothripsis in Pa102C and Pa227C  
ix 
 
Figure 4.1 ………………………………………...………….………….……….……...…....… 72 
Integrative approach towards identifying new FPC predisposition genes 
Figure 4.2 ………………………………………...………….………….……….…….....…..… 73 
















Familial Pancreatic Cancer 
Pancreatic ductal Adenocarcinoma (PDAC) has a dismal 5-year survival rate of 6%, which has 
remained relatively unchanged for decades, despite huge improvements in the survival of other cancers (1). 
The well-defined molecular progression of PDAC includes the driver genes KRAS, TP53, CDKN2A/p16, 
and DPC4/SMAD4 (2).  About 10% of PDAC cases occur in familial aggregate of two or more affected 
first-degree relatives, the definition of familial pancreatic cancer (FPC) (3, 4). Early onset is a hallmark of 
most familial cancer syndromes, including hereditary breast and ovarian cancer (BRCA1, BRCA2), familial 
adenomatous polyposis (APC), hereditary non-polyposis colorectal cancer (MLH1, MSH2, MSH6, PMS2), 
and familial atypical multiple mole melanoma syndrome (p16) (5-8). In contrast, an earlier age of onset is 
not an obvious hallmark of FPC (9, 10). In Chapter 2, I perform a qualitative analysis of the literature to 
confirm the common opinion that the age of onset of familial and sporadic PDAC cases is similar.  
Identifying Biomarkers for Early Detection 
 Early detection alone could increase the 5 year survival 5-fold, given that the 5-year survival rate 
of a localized tumor approached 25% (1). Recent research has highlighted that the window of opportunity 
for early detection is over a decade (11). Molecular testing of non-invasive liquid biopsies can make early 
detection practical in a broader population. Such molecular testing could utilize tumor-specific mutations in 
PDAC driver genes (e.g. KRAS) or tumor-specific structural variants (e.g. personalized analysis of 
rearranged ends, PARE) (12, 13).  
In Chapter 2, I show that the sporadic PDAC driver genes are also altered in FPC, and at a similar 
prevalence. Because FPC shares the sporadic PDAC signature mutations, these could be included in early 
detection tests and the gene panels currently in development could also be used in FPC kindreds for early 
detection. The shared driver genes may also explain the similar age of onset in familial and sporadic 
PDAC. 
PARE analysis relies on tumor-specific structural variants (SVs), which can be identified from 
paired-end next generation sequencing data. In Chapter 3, I characterize the SV landscape of FPC 
homozygous deletions (HDs) at nucleotide-resolution using the combination of high density SNP 
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microarray and paired-end whole genome sequencing (WGS); this information is critical when designing 
PARE assays.  
Discovery of TransFlip Mutations 
During our SV analysis in Chapter 3, I discovered a novel class of SVs that are the combination 
of a translocation on one side of the deletion and an inversion on the other side, which we designate as 
“TransFlip mutations.” Strikingly, TransFlip mutations are enriched at deletions of the PDAC driver genes 
p16 and SMAD4. TransFlip mutations are ideal PARE targets, as they have not just one, but two novel 
junctions and often delete TSGs, thus providing selective advantage to the tumor cell.  
Challenges in the search for new FPC predisposition genes 
The known FPC predisposition genes account for less than 20% of FPC cases, and include 
BRCA2, PALB2, ATM, STK11/LKB1, CDKN2A/p16, APC, PRSS1, SPINK1, and the mismatch repair genes 
(MLH1, MSH2, MSH6, PMS2) (Table 1) (14-17). In Chapter 4, I outline our strategy we used to identify 
new FPC predisposition genes, using an integrated approach of conventional karyotype, high density SNP 
microarray, whole exome sequencing (WES), whole genome sequencing (WGS), and RNA-Seq. The lack 
of a bona fide candidate predisposition gene, despite our extensive analysis, highlights the challenges in 
identifying new FPC predisposition genes, and raises the possibility that this cancer results from multiple 










Peutz-Jeghers Syndrome (PJS) STK11/LKB1 132X 
Hereditary Pancreatitis PRSS1, SPINK1 50-90X 
Familial Atypical Multiple Mole Melanomas (FAMMM) CDKN2A/p16 13-22X 
Hereditary Breast and Ovarian Cancer Syndrome (HBOC) BRCA2, PALB2 3-10X 
Hereditary Non-Polyposis Colorectal Cancer (HNPCC) MLH1, MSH2, MSH6, PMS2 9X 
Familial Adenomatous Polyposis (APC) APC Up to 4X 
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 Pancreatic ductal adenocarcinoma (PDAC) is nearly uniformly lethal, with a median overall 
survival in 2014 of only 6 months.  The genetic progression of sporadic PDAC (SPC) is well established, 
with common somatic alterations in KRAS, p16/CDKN2A, TP53, and SMAD4/DPC4.  Up to 10% of all 
PDAC cases occur in families with 2 or more affected first-degree relatives (familial pancreatic cancer, 
FPC), but these cases do not appear to present at an obviously earlier age of onset.  This is unusual because 
most familial cancer syndrome patients present at a substantially younger age than that of corresponding 
sporadic cases.  Here we collated the reported age of onset for FPC and SPC from the literature. We then 
used an integrated approach including exomic sequencing (WES), whole genome sequencing (WGS), RNA 
sequencing (RNA-Seq), and high density SNP microarrays to study a cohort of FPC cell lines and 
corresponding germline samples.  We show that the four major SPC driver genes are also consistently 
altered in FPC and that each of the four detection strategies was able to detect the mutations in these genes, 
with one exception. We conclude that FPC undergoes a similar somatic molecular pathogenesis as SPC, 







While patients with several different forms of cancer survive longer after diagnosis than in the 
past, the 5-year survival rate of patients with pancreatic ductal adenocarcinoma cancer (PDAC) has 
remained relatively unchanged over the past 5 decades (1).  As many as 10% of PDAC have a hereditary 
component (familial PDAC, FPC), defined as at least two first-degree relatives with PDAC (3, 4).  Known 
susceptibility genes include BRCA1, BRCA2, PALB2, ATM, STK11, PRSS1, SPINK1, and DNA mismatch 
repair genes, but all together these explain less than 20% of familial pancreatic cancer cases (14-17).  
PDAC is notoriously lethal because patients present late in the disease process and the cancers are 
chemorefractory.  Importantly, the 9% of cases that present with the tumor confined to the pancreas have a 
5-year survival rate of 24%, supporting the notion that lesions detected early enough can be cured (1).  To 
focus early detection resources, it is important to identify patients at particularly high risk, such as those 
with familial predispositions. 
The molecular progression of SPC is well-established both histologically and molecularly (2).  
The high-prevalence SPC driver genes are KRAS (>90% of PDAC), CDKN2A/p16 (95%), TP53 (50-75%), 
and SMAD4/DPC4 (55%) (18-21).  PDACs commonly arise from pancreatic intraepithelial neoplasia 
(PanIN) or Intraductal Papillary Mucinous Neoplasm (IPMN) precursor lesions.  While the pathology of 
FPC has been shown not to differ from that of apparently sporadic disease, FPC patients have been shown 
to have significantly more precursor lesions as well as higher grade precursor lesions when compared to 
patients with sporadic disease (22-24). Knowing the genes involved in FPC molecular progression is 
essential to designing effective early detection strategies (25). 
Early onset is a hallmark of most familial cancer syndromes, including hereditary breast and 
ovarian cancer (BRCA1, BRCA2), familial adenomatous polyposis (APC), hereditary non-polyposis 
colorectal cancer (MLH1, MSH2, MSH6, PMS2), and familial atypical multiple mole melanoma syndrome 
(p16) (5-8).  In contrast, an earlier age of onset is not an obvious hallmark of FPC (9, 10). How can one 
possibly inherit a predisposition to a cancer without an obvious acceleration of the phenotype?  This 
question challenges our current understanding of familial cancer syndromes and the canonical two-hit 
hypothesis (26, 27). 
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In the study, we first collated the age of onset in FPC and SPC reported in the literature to validate the 
opinion that the age of onset of familial and sporadic PDAC cases was similar. We then determined the 
status of known SPC driver genes in our own FPC cohort, a unique resource of eighteen FPC cell lines that 
we have generated over the past decade. We used an integrated approach including high density SNP 
microarrays, exomic sequencing, whole genome sequencing, and RNA-sequencing to investigate those 
genes involved in FPC progression.  Finally, having established a consensus for each gene in each sample, 






Materials and Methods 
Case Selection 
This study was reviewed and approved by the Institutional Review Board at Johns Hopkins 
Medical Institutions, and informed consent was obtained from all study participants. Familial pancreatic 
cancer was defined as a pancreatic cancer that arose in a patient with at least a first-degree relative with 
pancreatic cancer (i.e. 2 or more affected first-degree relatives). Cancer cell lines were established from 
familial pancreatic cancers and matched normal DNA from the patients was obtained from Epstein-Barr 
virus (EBV) transformed lymphoblasts or frozen tissue (28). Tumor-normal pair matching was confirmed 
by STR analysis of 9 loci and Amelogenin using ABI Profiler kit (Life Technologies, Carlsbad, CA) and 
size-separated on an ABI CE3130xl instrument (Life Technologies). The data from 94 SPC and 7 FPC (4 
from discovery, 3 from prevalence) were previously reported (20). An unpaired, two-tailed t-test was used 
to determine if the mean age of onset difference between our familial and sporadic cases was statistically 
significant. 
Collation of Reported Age of Onset 
Literature reporting age of onset in FPC (excluding hereditary pancreatitis) and SPC were 
collected from PubMed. Only the most recent study was used when multiple studies employed the same 
patient registry, on the assumption that previous reported families would be included in subsequent reports 
and therefore exclude redundant cases. Studies were stratified based on study type (population or referral) 
and statistic reported (mean or median). 
Preparation of Genomic DNA and RNA 
Genomic DNA was extracted from early passage cell lines and matched normal EBV-transformed 
lymphoblasts or frozen normal tissue using QIAamp DNA mini kit (Qiagen, Valencia, CA), per 
manufacturer’s instruction. RNA was extracted from cell lines using RNeasy mini kit (Qiagen), per 
manufacturer’s instruction.  A HPDE (human pancreatic ductal epithelium) cell line was used as a normal 





High Density SNP Microarray 
 The Omni2.5 array (Illumina, San Diego, CA) was used to analyze cancer cell lines and matched 
normal samples at 2,379,855 (2.5M) SNP loci.  Analysis was carried out with Genome Studio with the 
following criteria: an average LogR Ratio (LRR) ≤ -2.0 for homozygous deletions; LRR of 0-0.53 and B 
Allele Frequency of 0 or 1 for loss of heterozygosity (LOH); and an average LRR ≥ 1.4, with at least 1 SNP 
LRR ≥ 2.0, for amplifications. At least 4 SNPs must fit criteria for the region to be called an alteration and 
boundaries were the first and last SNPs that meet criteria.  Adjacent deleted or amplified regions (within 
100kb) were considered to be one alteration. Given that half or more of the p16 and SMAD4 inactivations 
are homozygous deletions, we excluded the 4 FPC and 81 SPC cases without SNP microarray data, in the 
analysis of p16 and SMAD4 genes. 
Genomic DNA Libraries and Exomic Sequencing  
Genomic DNA libraries were prepared using 1 μg of genomic DNA and human exome capture 
was performed following a modified protocol from Agilent's SureSelect Paired-End Version 2.0 Human 
Exome Kit (Agilent, Santa Clara, CA) as previously described (30). Briefly, captured DNA libraries were 
sequenced with GAIIx Genome Analyzer, yielding 150 bp (2 × 75 bp) from the final library fragments, to 
200x coverage. Sequencing reads were analyzed and aligned to human genome hg18 with the Eland 
algorithm in CASAVA 1.7 software (Illumina). The Database of Single Nucleotide Polymorphisms was 
used in the analysis of whole-exome sequencing data (dbSNP).  Mutations were visually confirmed in the 
aligned files. 
Whole Genome Sequencing 
Sequencing on an Illumina HiSeq 2000 (Illumina) was carried out at 60X coverage for cancers and 
30X coverage for matched normal by Personal Genome Diagnostics (Baltimore, MD) using 3 μg of 
genomic DNA and generating 200 bp (2 x 100 bp paired reads) per fragment. Reads were aligned to human 
genome (hg19) with Eland v.2 algorithm in CASAVA 1.7 software (Illumina). 
cDNA Libraries and RNA Sequencing 
A total of 5 μg of total RNA was depleted of ribosomal RNA using ribominus and cDNA libraries 
were prepared using TruSeq Stranded Total RNA Sample Preparation (Illumina), per the manufacturer’s 
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instructions. Paired-end sequencing, resulting in 100 bp reads was carried out on an Illumina HiSeq to a 
level of 50M reads. RSEM was used to align the sequences to human genome hg19 (31).  Alterations were 






Previous investigations have noted a similar age of onset of SPC and FPC. To comprehensively 
examine this, we culled studies reporting FPC and SPC age of onset and published from 1991-2013 (n=15). 
To avoid overweighting the same families, we used only the most recent study when multiple studies 
reported on the same dataset.  The collated studies have reported mean or median ages of 60 to 74 for SPC 
patients and 52 to 69 for FPC patients (Figure 1, Supplemental Table 1). Due to potential ascertainment 
bias, we separated the studies that reported age of onset in a population unselected based upon family 
history (Figure 1A) versus those from family registries (Figure 1B).  The mean age of PDAC diagnosis 
from 1973-2000 SEER data is 70 years (33). In our small cohorts of FPC and SPC, there was no obvious 
difference in age (FPC cohort: mean 64 years (range:  42-81); SPC cohort:  66 years (range: 36-85)) (Table 
1, Supplemental Table 2).  The lower age of both of the cohorts we analyzed (FPC and SPC) compared to 
SEER was likely attributable to ascertainment or referral bias. There appears to be a greater difference in 
the referral based studies, likely because the vast majority of samples in our study underwent surgical 
resection. We have intentionally omitted statistical comparison of the groups because of the invalidity in 
comparing means and medians, and the small sample size that would exist without pooling these two 
statistics. 
 The molecular progression of SPC is well-documented, with common somatic alterations in the 
four driver genes KRAS, CDKN2A/p16, TP53, and SMAD4/DPC4, in addition to many other low 
prevalence genes (20, 21).  In an attempt to identify new FPC predisposition genes, we performed a 
comprehensive genomic analysis of our 16 FPC cell lines. No strong candidates for predisposition genes 
were identified in these samples.  We also determined the mutational status of the four SPC driver genes in 
these 16 FPC samples as assessed by each of the four methods.  
Overall, the prevalence of alterations in the four SPC driver genes was similar in the 16 FPC 
PDACs and the 94 SPC PDACs (Figure 2A,B).  Activating KRAS mutations were identified in 16/16 
(100%) of FPC PDACs, predominately at codon 12 (94%: 63% G12D, 19% G12V, and 13% G12R) but 
with one case at codon 61 (6%, Q61H) (Figure 2B, Supplemental Table 3).  Of the 94 sporadic PDACs, all 
but one had an activating KRAS mutation (99%).  The majority of KRAS mutations in the SPC PDACs were 
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also at codon 12 (95%: 50% G12D, 31% G12V, and 12% G12R).  Four SPC PDACs had codon 61 
mutations (3 Q61H, 1 Q61R), and one SPC PDAC had two different activating KRAS mutations (G12V and 
G13C). 
CDKN2A/p16 was inactivated in 100% (12/12, the 4 cases without SNP microarray data were 
excluded) by homozygous deletion (9/12, 75%) or single base substitution with loss of heterozygosity 
(LOH) (3/12, 25%), of the FPC PDACs, compared to only 62% (8/13, the cases without SNP microarray 
data were excluded) of the SPC PDACs (p=0.04, Figure 2B, Supplemental Table 4). Alterations of the 
CDKN2A gene are reported to occur in 95% of SPC PDACs, with epigenetic silencing accounting for about 
15% of this inactivation (34). As we did not assess epigenetic changes, the actual fraction of cases with 
somatically altered CDKN2A in Supplemental Table 4 is likely an underestimate.     
TP53 was mutated in 88% (14/16) of FPC PDACs, by single base substitution with LOH (10/14), 
frameshift with LOH (2/14), or biallelic mutation (2/14) (Figure 2B, Supplemental Table 5).  Of the 94 
sporadic PDACs, 82 (87%) had inactivating TP53 mutations.  The mutation types included biallelic 
mutations (1/82), single base substitutions with LOH (64/82), frameshifts with LOH (15/82), and 
homozygous deletions (2/82). 
SMAD4/DPC4 was inactivated in 75% (9/12, the 4 cases without SNP microarray data were 
excluded) of FPC PDACs, by homozygous deletion (5/9), single base substitution with LOH (3/9), and 
frameshift with LOH (1/9) (Figure 2B, Supplemental Table 6). Of the 13 sporadic PDACs (the cases 
without SNP microarray data were excluded), 62% had inactivated SMAD4.  The mutation types included 
single base substitutions with LOH (2/8), frameshifts with LOH (3/8), and homozygous deletions (3/8). 
 Having established a consensus gene mutation status, we retrospectively determined the ability of 
each genome-wide tool to detect the mutations. We first categorized the mutations as homozygous 
deletions (HDs), point mutations (including single base substitutions, frameshift deletions and insertions), 
and loss-of-heterozygosity (LOH) events. We then studied the ability of each tool to detect these three 
types of mutations in the 4 driver genes (Table 2). 
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Homozygous deletions are common in the tumor suppressors CDKN2A/p16 and SMAD4/DPC4 
and were detected reliably by SNP microarray, WES, WGS, and RNA-Seq.  For only one homozygous 
deletion (Figure 3A,B), the standard WGS Illumina pipeline for calling copy number alterations missed a 
p16 homozygous deletion (sample PA222C), clearly deleted by visual inspection of WGS data (Figure 3C). 
The homozygous deletion included 17kb of the 5’ end of p16 transcript variant 4 (NM_058195), but did not 
result in the deletion of any DNA sequence corresponding to transcript variants 1, 3, 5 (NM_000077, 
NM_058197, and NM_001195132) (Figure 3A,B). The later transcript variants encode the p16(INK4) 
isoform, a CDK inhibitor, while transcript variant 4 encodes a structurally distinct p14(ARF) which 
stabilizes TP53 by sequestering MDM2. Both isoforms are normally expressed in the pancreas. 
Importantly, neither the p14ARF or p16INK4a transcripts are expressed according to the RNA-Seq data 
(Figure 3E), a result of the loss of p14ARF’s first exon and p16(INK4)’s promoter sequence, respectively.  
This 37kb homozygous deletion was identified by WES, RNA-Seq, and high density SNP microarray, and 
the deletion’s breakpoints were remarkably concordant across these methods (Figure 3B-F). Because the 
WGS results were initially discordant, we used multiplex ligation-dependent probe amplification (MLPA) 
to confirm the homozygous deletion (Figure 3G). That only 1 of the 4 alternative transcripts is included in 
the homozygous deletion explains why this was missed by the WGS using the standard Illumina pipeline. 
This highlights the importance of the reference transcript used in a NGS mapping algorithm and the 
potential utility of remapping to known deletions, such as p16 in the case of PDAC, especially at lower 
read depths.  
Point mutations and LOH in KRAS, p16, TP53, and SMAD4 were all detected by WES, WGS, and 
RNA-Seq.  High density SNP microarray could of course not detect any of the point mutations in the four 
driver genes.   However, it is likely that a custom SNP microarray could be designed to detect mutations in 
hotspots in KRAS. Where LOH in p16, TP53, and SMAD4 genes was detected, it was detected equally by 
all of the methods. In the 2 cases with biallelic TP53 mutations, there was no evidence of LOH, as 
expected. 
We also investigated the mutation status of genes implicated at a lower frequency in PDAC, but 
reported to be mutated in cystic precursors, pancreatic neuroendocrine tumors (PanNETs), or implicated as 
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FPC predisposition genes. MLL3 has been reported to be mutated in 9% of PDACs (20, 35).  Here, MLL3 
was mutated in 17% (2/12) FPC PDACs. Both cases were single base substitutions (nonsense mutation 
with LOH in PA11X and bi-allelic missense mutations in PA18C). The genes implicated in pancreatic 
cystic lesions (GNAS, RNF43, CTNNB1, and VHL) were not mutated in any FPC case (36, 37).  ATRX, 
DAXX, and MEN1 are reported to be mutated in PanNETs, and ATRX was homozygously deleted in 1 (8%) 
FPC case (PA102C) (30). DAXX and MEN1 however, were not mutated in any FPC PDACs, and no clearly 






We confirm, through our qualitative analysis of the literature, that most studies do not indicate a 
large difference in the age of onset between SPC and FPC.  While some studies do show a slight difference 
in the age of onset, part of this difference could be due to ascertainment biases.  Some studies have shown a 
slightly lower age of onset in FPC compared to SPC in their cohorts (38-44).  One study even showed a 
slightly later onset in their FPC group (45), however most studies to date have shown a similar age of onset 
(Supplemental Table 1) (46-55). The field would benefit from a rigorous meta-analysis of FPC age of 
onset. 
Our study also showed that FPC PDACs harbor the same high prevalence genetic alterations that 
have been identified in SPC PDACs (Figure 2B).  One purpose of analyzing driver data prevalence is to 
identify “holes”, genes with lower than expected mutation prevalence, under the hypothesis that a 
homologue or pathway-related gene could be defective in the germline. A similar approach led to the 
elegant discovery of germline MYH mutations in familial colorectal cancers that were phenotypically 
similar to attenuated familial adenomatous polyposis, but lacked germline APC mutations (56).  From our 
data, there are no such “holes.” This finding confirms and builds upon a previous study that found that 
familial and sporadic pancreatic cancers had similar prevalence of mutations in the three SPC driver genes 
they assessed (34).  
The late detection of pancreatic cancers contributes to the lethality of the disease.  Much work has 
been done in the area of non-invasive early detection tests, using molecular signatures of pancreatic cancer 
– notably, the KRAS codon 12/13 mutation hotspot.  Because FPC shares the SPC molecular signature 
mutations, these could be included in early detection tests and the gene panels currently in development 
could also be used in familial pancreatic kindreds for early detection and molecular relapse. 
Assuming that FPC and SPC have a similar age of onset, how can one inherit a predisposition to a 
disease without accelerating its age of onset?  Unfortunately, our study did not provide any great insights 
into this question and it remains unanswered.   We note, however, that there is precedent in PDAC, even 
when the causative genes are known.   For example, in patients with Familial Atypical Multiple Mole 
Melanoma (FAMM) syndrome, p16 germline mutations confer a significantly earlier age of onset for 
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melanoma, but not for PDAC (6, 52, 57, 58). These observations support the idea that it is the pancreatic 
tissue rather than the gene that is responsible for the curious lack of age dependence on the presence of 
hereditary predisposition genes.  The mechanisms underlying this difference represent an important area for 
future study as it may shed light on PDAC pathogenesis in general.   
We employed an integrative strategy to more comprehensively detect alterations in FPC than 
previous reports.  Combining WES, WGS, and RNA-Seq allowed for a greater coverage of gene-coding 
regions, particularly in expressed genes (Table 2). The importance of gene transcript choice in identifying 
alterations, such as homozygous deletions, in next generation sequencing data was highlighted by the 
PA222C homozygous deletion of p16 initially missed by WGS analysis, but obvious upon visual inspection 
of the reads (Figure 3). Other than this one example, the methods were remarkably concordant. High 
density SNP microarrays strengths are identifying LOH and large homozygous deletions, both hallmarks of 
tumor suppressor genes.   
We conclude that FPC and SPC undergo similar pathogenesis permitting the same gene targets to 





Figure 2.1. Reported age of onset for SPC and FPC, collated from the literature. Literature was 
separated based on a population-based or b referral cohorts, reported as means (filled symbols) or medians 
(empty symbols). Symbol sizes are adjusted according to the number of individuals in the study [2*log(n)]. 





Figure 2.2. Summarized alterations in PDAC molecular progression genes, for SPC and FPC. a 
PDAC molecular progression model with reported percent alterations of the four driver genes in PanIN 
lesions. b Percent alterations of molecular progression genes in PDAC cancers from SPC and FPC cohorts. 
As expected, the mutation prevalence in PDACs in panel b are higher than the early PanIN lesions in panel 





Figure 2.3. CDKN2A/p16 homozygous deletion (HD) initially missed by WGS. Visualization of WGS 
reads for p16 region (hg19, chr9:21,951,176-22,102,475) in PA222C sample using IGV and Karyostudio. 
The 2 protein isoforms of p16 (p14(ARF) and p16(INK4), blue) are shown as well as the adjacent genes, 
C9orf53 and CDKN2B-AS1 (a). There is clear agreement across the methods for the consensus 97kb HD 
boundaries (b). The homozygous deletion of p16 was not called by the standard Illumina pipeline for WGS 
data, despite a clear confirmation of the 5’ HD by visual inspection, due to reference transcript choice (c). 
The HD was detected by WES, as evidenced by the lack of reads (d). RNA-Seq produced no high quality 
reads that mapped to this deleted region, but there were reads upstream (MTAP) and downstream 
(DMRTA1) of the HD (e, line break indicates upstream or downstream reads shows). High density SNP 
microarray detected the HD (red LogR line drops to -2.00 and scattered B allele frequencies) and the 
flanking LOH regions (red LogR line at -1 and B allele frequencies at 0 or 1) (f). MLPA probes were used 




Table 2.1. Familial (FPC) cohort demographics  
Case Age at Diagnosis Sex Additional Family History of Pancreatic Cancer  
Pa007C* 80s F Father, Mother 
Pa009C* 60s F Brother, Paternal Uncle 
Pa011X* 70s F Father 
Pa018X* 70s F Brother 
Pa101C 40s M Father 
Pa102C 60s F Sister 
Pa147X* 70s M Brother, Mother 
Pa170X* 40s M Brother 
Pa212X* 60s M Mother 
Pa222C 70s M Father, Paternal Grandfather, Paternal Uncle 
Pa223C 60s F Brother, Cousin 
Pa227C 60s F Father 
Pa228C 60s F Brother 
Pa229C 40s M Mother 
Pa230C 60s F Father 
Pa231C 60s M Father, Mother, Paternal Grandfather 





Table 2.2: Relative power of each method to detect common alterations 




Altered WES WGS 
SNP 
microarray RNA-Seq 
KRAS OG Mut 7 7 (100%) 7 (100%) 0 (0%) 7 (100%) 
        
TP53 TSG Mut 7 7 (100%) 7 (100%) 0 (0%) 7 (100%) HD 0 na na na na 
        
CDKN2A/ 
p16 TSG 
Mut 3 3 (100%) 3 (100%) 0 (0%) 3 (100%) 
HD 4 4 (100%) 4* (100%) 4 (100%) 4 (100%) 
        
SMAD4/ 
DPC4 TSG 
Mut 2 2 (100%) 2 (100%) 0 (0%) 2 (100%) 
HD 4 4 (100%) 4 (100%) 4 (100%) 4 (100%) 
*One p16 mutation was not reported altered by the standard Illumina pipeline, but visualization of the bam file clearly showed a HD. 
Oncogene (OG), tumor suppressor gene (TSG), mutation (MUT, includes frameshifting insertions and deletions and point mutations), 






Supplemental Table 2.1: Summary of the literature collated for age of onset analysis 
Study PDAC Type 
Study 
Type Statistic n 
Age of Onset 
(yrs) 
James, et al. Cancer 2004 Familial Population Mean 30 57.6 
Ghadirian, et al. Int J Pancreatol 1991 Familial Population Mean 14 65.0 
Matsubayashi, et al. Pancreas 2011 Familial Population Mean 40 67.9 
Brandt, et al. Ann Oncol 2008* Familial Population Median 2,500 56.3 
Bartsch, et al. Int J Cancer 2004 Familial Population Median 17 61.0 
Ji, et al. Pancreatology 2008 Familial Population Median 150 64.0 
McWilliams, et al. Clin Gastroenterol 
Hepatol 2006 Familial Population Median 74 65.5 
Verna, et al. Clin Cancer Res 2010 Familial Referral Mean 51 52.0 
Rulyak, et al. Gastroenterol 2003 Familial Referral Mean 176 61.0 
Couch, et al. Cancer Epidemiol 
Biomarkers Prev 2007 Familial Referral Mean 350 62.8 
Iqbal, et al. Br J Cancer 2012 Familial Referral Mean 8 63.8 
Petersen, et al. Cancer Epidemiol 
Biomark Prev 2006 Familial Referral Mean 798 65.4 
Mocci, et al. Cancer Epidemiol 
Biomarkers Prev 2013 Familial Referral Mean 417 66.2 
Brune, et al. JNCI 2010 Familial Referral Mean 29 68.5 
Anderson, et al. Am J Gastroenterol 
2012 Familial Referral Median 28 65.6 
James, et al. Cancer 2004 Sporadic Population Mean 796 61.0 
Ghadirian, et al. Int J Pancreatol 1991 Sporadic Population Mean 165 65.0 
Matsubayashi, et al. Pancreas 2011 Sporadic Population Mean 537 65.2 
SEER_1973-2000 Sporadic Population Mean 
72,70
0 70.0 
Brandt, et al. Ann Oncol 2008* Sporadic Population Median 
25,00
0 59.7 
Bartsch, et al. Int J Cancer 2004 Sporadic Population Median 456 63.0 
Ji, et al. Pancreatology 2008 Sporadic Population Median 
19,33
6 67.5 
McWilliams, et al. Clin Gastroenterol 
Hepatol 2006 Sporadic Population Median 134 69.6 
SEER18_2006-2010 Sporadic Population Median 
40,67
6 71.0 
Rulyak, et al. Gastroenterol 2003 Sporadic Referral Mean 83 69.0 
Brune, et al. JNCI 2010 Sporadic Referral Mean 8 73.8 
Anderson, et al. Am J Gastroenterol 





Supplemental Table 2.2: Age of onset in our SPC and FPC cohorts  
Statistic  SPC FPC 
n 94 16 
Min age 36 42 
Max age 85 81 
Mean age 65.5 64.3 
SD 10.2 11.2 






Supplemental Table 2.3: KRAS mutation spectrum in FPC vs. SPC, by amino acid substitution  
Alteration FPC SPC 
WT 0 0% 0 0% 
G12D 8 67% 9 69% 
G12R 0 0% 0 0% 
G12V 3 25% 3 23% 
Q61H 1 8% 1 8% 
TOTAL 12   13   

























Supplemental Table 2.4: CDKN2A/p16 mutation spectrum in FPC vs. SPC 
Alteration FPC SPC 
WT  0 0% 5 38% 
Biallelic mutations 0 0% 0 0% 
SBS 0 0% 0 0% 
Fs/indel 0 0% 0 0% 
Mutation+LOH 3 25% 2 15% 
SBS 2 17% 2 15% 
Fs/indel 1 8% 0 0% 
HD 9 75% 6 46% 
TOTAL 12  13  
wildtype (WT), single base subsititution (SBS), frameshifting insertion or deletion (FS/indel), loss                          























Supplemental Table 2.5: TP53 mutation spectrum in FPC vs. SPC   
Alteration FPC SPC 
WT  1 8% 0 0% 
Biallelic mutations 0 0% 0 0% 
SBS 0 0% 0 0% 
Fs/indel 0 0% 0 0% 
Mutation+LOH 11 92% 11 85% 
SBS 8 67% 9 69% 
Fs/indel 3 25% 2 15% 
HD 0 0% 2 15% 
TOTAL 12   13   
wildtype (WT), single base subsititution (SBS), frameshifting insertion or deletion (FS/indel), loss                           














Supplemental Table 2.6: SMAD4/DPC4 mutation spectrum in FPC vs. SPC  
Alteration FPC SPC 
WT  3 25% 5 38% 
Biallelic mutations 0 0% 0 0% 
SBS 0 0% 0 0% 
Fs/indel 0 0% 0 0% 
Mutation+LOH 4 33% 5 38% 
SBS 3 25% 2 15% 
Fs/indel 1 8% 3 23% 
HD 5 42% 3 23% 
TOTAL 12   13   
wildtype (WT), single base subsititution (SBS), frameshifting insertion or deletion (FS/indel), loss of 
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Pancreatic ductal adenocarcinoma (PDAC) is driven by the inactivation of the tumor suppressor 
genes (TSGs), CDKN2A/p16 and DPC4/SMAD4, commonly by homozygous deletions (HDs). Using a 
combination of high density SNP microarray and whole genome sequencing (WGS), we fine-mapped novel 
breakpoints surrounding deletions of p16 and SMAD4 and characterized them by their underlying structural 
variants (SVs). Only one third of p16 and SMAD4 deletions (6 of 18) were simple interstitial deletions, 
rather, the majority of deletions were caused by complex rearrangements, specifically, a translocation on 
one side of the TSG in combination with an inversion on the other side. We designate these as “TransFlip” 
mutations. Characteristics of TransFlip mutations are: (1) a propensity to target the TSGs p16 and SMAD4 
(p<0.005), (2) not present in the germline of the examined samples, (3) non-recurrent breakpoints, (4) 
relatively small (47bp to 3.4kb) inversions, (5) inversions can be either telomeric or centromeric to the 
TSG, and (6) non-reciprocal, and non-recurrent translocations. TransFlip mutations are novel complex 
genomic rearrangements with unique breakpoint signatures in pancreatic cancer.  We hypothesize that they 





Homozygous deletions (HD) are a common mechanism by which tumor suppressor genes (TSGs) 
are inactivated in cancer, and are a common mapping tool for the discovery of TSGs (Hahn, et al. 1996; 
Lee, et al. 1987). HDs can range in size from kilobases to megabases, and are enriched at fragile sites and 
have been associated with chromothripsis (Bignell, et al. 2010; Stephens, et al. 2011). HDs are often the 
result of double-stranded DNA breaks (DSB), which can be repaired through a variety of mechanisms 
including homologous, microhomologous, and non-homologous pathways (Supplemental Table1). Non-
homologous end joining (NHEJ), microhomology-mediated end-joining (MMEJ), and microhomology-
mediated break-induced replication (MMBIR, also known as fork stalling and template switching, FoSTeS) 
are the dominant pathways by which DSB can be repaired, and each of these mechanisms manifests 
differently in the repaired DNA (Chiang, et al. 2012). Recent research has highlighted the additional 
mechanisms of chromoplexy, LINE1 (L1) 3’ transduction, and breakage-fusion-bridge cycles (BFB) (Baca, 
et al. 2013; Campbell, et al. 2010; Tubio, et al. 2014). 
Cyclin-Dependent Kinase Inhibitor 2A (CDKN2A/p16) and Deleted in Pancreatic Carcinoma 
(DPC4/SMAD4) are two of the most commonly homozygously deleted TSGs in cancer (Cox, et al. 2005). 
In pancreatic ductal adenocarcinoma (PDAC), p16 and SMAD4 homozygous deletions are seen in about 
40% and 30% of cases, respectively (Biankin, et al. 2012; Caldas, et al. 1994; Hahn, et al. 1996; Jones, et 
al. 2008). The p16 locus, at 9p21, encodes 2 distinct proteins, p16(INK4A) and p14(ARF1), which regulate 
cyclin-dependent kinases and the tumor suppressor p53, respectively. The SMAD4 locus, at 18q21.1, 
encodes a transcription factor in the TGF-beta signaling pathway.  
In this study, we first identified somatic HDs in PDAC cancer cell lines using high density SNP 
microarrays. We then determined the precise breakpoints and characterized the underlying complex 
structural rearrangements (SV; interstitial deletion, translocation, inversion) using paired-end whole 
genome sequencing (WGS). We further characterized all deletions (heterozygous and homozygous) 
involving the PDAC TSGs, p16 and SMAD4, and confirmed rearrangements by PCR amplification and 
bidirectional Sanger sequencing across the breakpoints. We report two distinct patterns of TSG deletions: 
the first is simple interstitial deletion, and second, are deletions that result from the combination of an inter-
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chromosomal translocation and inversion flanking the HD of the TSG, designated here as TransFlip 
mutations. For somatic HDs in other regions of the genome, TransFlip mutations are rare but are an 
important mechanism by which TSGs are inactivated in PDAC, where TransFlip mutations occurred more 




Materials and Methods 
Preparation of Genomic DNA and Karyotyping 
Cancer cell lines were generated and matched normal DNA were obtained from 8 patients with 
familial pancreatic adenocarcinoma (FPC, defined as a patient with PDAC who is from a kindred in which 
at least two family members were diagnosed with PDAC) as previously described (Kamiyama, et al. 2013; 
Norris, et al. 2014). STR analysis using ABI Profiler kit (Life Technologies, Carlsbad, CA) and 3130xL 
Genetic Analyzer (Life Technologies) confirmed tumor-normal pair matching, and xenografting in nude 
mice confirmed that the cell line isolated was the neoplastic component. Genomic DNA was extracted from 
early passage (<20 passages) cell lines and matched normal EBV-transformed lymphoblasts or frozen 
normal tissue using QIAamp DNA mini kit (Qiagen, Valencia, CA), per manufacturer’s instruction. Cell 
lines were karyotyped using methodology previously described (Griffin, et al. 1994). For comparison, DNA 
from the tumors of sporadic PDAC patients was obtained, as part of the rapid autopsy program previously 
reported (Embuscado, et al. 2005). 
High Density SNP Microarray 
The Omni2.5 array (Illumina, San Diego, CA) was used to analyze cancer cell lines and matched 
normal samples, as previously described (Norris, et al. 2014). GenomeStudio and KaryoStudio (Illumina) 
were used to identify regions of homozygous deletion, heterozygous deletion, and loss of heterozygosity 
(LOH), and matched normal was used to remove germline deletions. These approximate coordinates were 
used to inform breakpoint analysis of WGS data. 
Whole Genome Sequencing (WGS) 
Sequencing on an Illumina HiSeq 2000 (Illumina) was carried out at 60X coverage by Personal 
Genome Diagnostics (PGDx, Baltimore, MD) using 3μg of genomic DNA and generating 200 bp (2 x 
100bp reads) sequence per fragment (median total size approximately 500bp). Paired reads were aligned to 
human genome (hg19) with Eland v.2 algorithm using the CASAVA 1.7 software (Illumina). 
Breakpoint Characterization and Sanger Sequencing Confirmation 
The exact genomic coordinates of p16 and SMAD4 deletion breakpoints were determined by 
visual inspection of aligned WGS reads in IGV (Broad Institute, Boston, MA).  The approximate genomic 
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coordinates from SNP microarray data were used as a starting point. The reads were visually scanned in 
IGV for evidence of a deletion breakpoint, specifically: (1) drop in coverage, (2) mismatched bases at read 
ends, (3) reads with aberrant insert size, (4) reads with aberrant pair orientation, (5) reads with pair mapped 
to another chromosome, or (6) flanking reads with unmapped pairs. Tumor DNA and matched normal were 
amplified with M13-tagged primers (Integrated DNA Technologies, Coralville, IA), designed with Primer3 
(Untergasser, et al. 2007), using Platinum PCR Super Mix (Life Technologies), per manufacturer’s 
protocol. Amplicons were size-separated using polyacrylamide gel electrophoresis (PAGE) and ethidium 
bromide staining, to confirm the presence of novel junctions in the tumor (cancer cell line and available 
primary tumor DNA for Pa227C, Pa228C, Pa229C, and Pa230C) and the absence in the normal DNA. 
Amplicons from tumor DNA were Sanger sequenced on the 3730xL DNA Analyzer (Life Technologies) 
and analyzed with Sequencher software (Gene Codes, Ann Arbor, MI). To eliminate the possibility of the 
TransFlip mutations being specific to familial PDAC, we confirmed the presence of both an interstitial 






Nucleotide Resolution of HDs 
During our attempts to identify FPC predisposition genes, we closely examined HD regions 
identified by high density SNP microarrays in a series of well-characterized FPC cell lines (Norris, et al. 
2014). Visual inspection of WGS data in IGV revealed abrupt loss of coverage at both breakpoints 
corresponding to regions first identified by the SNP microarray. Aberrantly mapped pairs and reads with 
“rainbow ends” (where half of the read IGV perfectly matches the reference and the other half has 
highlighted mispaired bases) flank both breakpoints (Figure 1). As expected, the mispaired bases of the 
“rainbow end” map to the other side of the HD for a simple interstitial deletion, the definition of split reads. 
Aberrantly mapped read pairs are colored by the IGV software to indicate a deletion, insertion, inversion, 
or translocation (Supplemental Figure 1). 
Simple Interstitial Deletions Underlie Most Somatic HDs 
Using this approach, we identified a total of 85 somatic HDs in our PDAC cancer cell lines from 8 
FPC patients. The number of somatic HDs varied by sample, from 3 (Pa101C) to 18 (Pa229C and Pa231C), 
with a median of 9.5.The majority (69/85, 81%) of all somatic HDs were simple, interstitial deletions, in 
which a segment of a chromosome arm was deleted and the ends joined (Figure 2A, Supplemental Tables 2 
and 3). The HDs associated with complex rearrangements (16/85, 19%) were categorized as inversion at 
one breakpoint and translocation at the other (TransFlip mutations, 7/16, 44%), inversion at both 
breakpoints (INV+INV, 6/16, 38%), intra-chromosomal translocation at both breakpoints (ICT+ICT 1/16, 
6%), or inter-chromosomal translocation at both breakpoints (TRANS+TRANS, 2/16, 13%). Deletions 
associated with complex rearrangements were significantly larger than interstitial HDs, with medians of 
153kb and 9kb deleted chromosome material respectively (p<0.05 by unpaired, two-tailed t-test) 
(Supplemental Table 2). Of the complex rearrangements, inversions produced the smallest HDs (median of 
57kb), while SVs involving translocations (TRANS+TRANS, ICT+ICT, and TransFlip mutations) 
produced significantly larger HDs (p<0.05 by unpaired, two-tailed t-test). 
While most interstitial deletions were intergenic (44/69, 64%), most (12/16, 75%) complex 
rearrangements resulted in the deletion of one or multiple gene(s) (Supplemental Table 3). Specifically, 
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TransFlip mutations were enriched at the PDAC TSGs p16 and SMAD4 HDs, compared to interstitials (4 of 
7 vs. 5 of 69, p<0.005 by Fisher’s exact test).  
Complex TransFlip mutations underlie many p16 and SMAD4 deletions in pancreatic cancer 
We then performed a comprehensive analysis of all p16 and SMAD4 deletions, including both 
homozygous and heterozygous deletions, in our PDAC cancer cell lines from 8 FPC patients. Deletions of 
p16 and SMAD4 were present in 7 samples each, with 18 total deletions producing the 2 heterozygous p16 
deletions (Pa102C, Pa230C), 5 homozygous p16 deletions (Pa101C, Pa222C, Pa228C, Pa229C, Pa231C), 3 
heterozygous SMAD4 deletions (Pa101C, Pa228C, Pa230C), and 4 homozygous SMAD4 deletions 
(Pa102C, Pa227C, Pa229C, Pa231C). These generated a total of 26 novel junctions (where interstitial 
deletions produce one novel junction and TransFlip mutations produce at least two novel junctions). All 26 
novel junctions were confirmed to be present in the cancer cell line by PCR and bidirectional Sanger 
sequencing, and absent in the matched normal sample. For 4 cases, the resected primary tumor was 
available (Pa227C, Pa228C, Pa229C, and Pa230C), and all corresponding novel junctions were present, 
confirming that these TransFlip mutations are not an artifact of cell culture. 
Complex SVs were found to underlie the majority (12/18, 66%) of p16 and SMAD4 deletions 
(Figure 2B). Most samples (5/8, 63%) had p16 and/or SMAD4 inactivated by a TransFlip mutation (Table 
1, Table 2, Supplemental Table 4). TransFlip mutations were coupled with LOH (p16, Pa229C and 
Pa231C), with an interstitial deletion (p16, Pa222C), or with another TransFlip mutation (SMAD4, Pa102C 
and Pa227C), to produce a HD of the TSG. TransFlip mutations and inactivation of the other allele of the 
TSGs by point mutation were mutually exclusive. In 5 samples with a point mutation in combination with a 
deletion of the TSG, 4 were the result of an INV rearrangement centromeric to the TSG and a terminal 
deletion (p16: 1/2; SMAD4: 3/3). The remaining one p16 heterozygous deletion was a simple interstitial 
deletion (Pa102C). 
Characteristics of TransFlip mutations in pancreatic cancer 
All translocations were non-reciprocal and conventional karyotyping only detected one of the 
translocation junctions (1/11, 9%, Pa231C’s t(4;9)(p15.1;p21.3)) (Supplemental Table 5). Inversion sizes 
ranged from 47bp to 3.3Mb for p16, and 53bp to 35.3Mb for SMAD4, and inversions associated with 
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TransFlip mutations were the shortest (47bp to 3.4kb). The inversion half of a TransFlip mutation was 
either centromeric or telomeric to the TSG deletion (Figure 3).  In addition to the characteristics above, 
TransFlip mutations were (1) confirmed in the primary tumors to exclude the possibility of cell culture 
artifact, and (2) were not present in any of the germline HDs in our samples. Distinct TransFlip mutations 
were also identified in sporadic PDAC samples. The fundamental features of TransFlip mutations are 
summarized in Table 3. 
Lack of alternate mechanisms of p16 and SMAD4 deletion 
For the simple interstitial deletions and the complex rearrangements targeting p16 and SMAD4, 
only 1 case had non-templated base insertion at the junction, which argues against NHEJ as the dominant 
mechanism (Supplemental Table 6). Microhomology was seen at the breakpoint in 12 of 14 (86%) p16 
novel junctions and 7/12 (58%) SMAD4 novel junctions. However, the median microhomology was only 1 
base for both p16 and SMAD4 (range of 0-7 and 0-3 bases, respectively). Therefore MMEJ and 
FoSteS/MMBIR are unlikely to be a dominant mechanism of the p16 and SMAD4 rearrangements in our 
cohort. Only one inversion of a TransFlip mutation (Pa222C SMAD4) had a relative copy number increase, 
indicative of a fold-back inversion, a manifestation of BFB cycles (Figure 4). BFB cycles do not explain 
the majority of TransFlip mutations. 
Chromothripsis of chromosomes 9 and 18 was seen in 1 and 2 cases, respectively (Supplemental 
Figure 2). Pa102C exhibited chromothripsis for both chromosomes and Pa227C exhibited chromothripsis 
for chromosome 18 (it did not have a p16 deletion). Chromothripsis-associated genome remodeling has 
been shown to be mostly intra-chromosomal translocations (rearrangements within the same chromosome), 
compared to the exclusively inter-chromosomal translocations of TransFlip mutations (Stephens, et al. 
2011). HDs have been associated with fragile sites, but fragile sites do not account for the spectrum of p16 
and SMAD4 rearrangements, since the breakpoints ranged over megabases and the translocation partners 
were not always in fragile sites themselves (Bignell, et al. 2010). 
 In most cases (p16: 13/14, 93% and SMAD4: 9/12, 75%), the regions involved in the 
rearrangement are not actively transcribed regions (here defined as having genes within 10kb of both sides 
of the breakpoint), and so chromoplexy is not a dominant mechanism. Only one case (p16 interstitial HD in 
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Pa101C) had repetitive elements of the same family (in this case, LINE-1) flanking both ends of the 
breakpoint (Supplemental Table 6). A recent report by Startek and colleagues highlights the requirement of 
an absolute minimum of 96% homology between LINE elements for mediating NAHR (Startek, et al. 
2015). The LINE-1 elements flanking the interstitial deletion of p16 in Pa101C (L1PA4, chr9:21,297,268-
21,300,617 and L1MA5A, chr9:22,121,352-22,123,446), have only 72% homology, arguing against a 
LINE-LINE-mediated NAHR event. L1 3’ transduction was not obvious at any p16 or SMAD4 
rearrangements, since all deletion junctions lacked the signatures of a non-templated polyA insertion and 






TransFlip mutations are more prevalent in p16 and SMAD4 deletions than simple interstitial 
deletions, in contrast to deletions elsewhere where the opposite is the case. The rearrangement breakpoints 
in TransFlip mutations are often in gene-free regions (they do not produce fusion transcripts), but TransFlip 
mutations always result in the deletion of one or more genes, with enrichment at TSGs. All translocations 
in TransFlip mutations were non-reciprocal, which is typical of epithelial tumors (Mitelman F 2015). The 
inversions associated with TransFlip mutations could be either centromeric or telomeric to the TSG, ranged 
from 47bp to 3.4kb in length, and only one was a fold-back inversion. Fold-back inversions have been 
reported in PDAC, but not in combination with translocations (Campbell, et al. 2010).  
To the best of our knowledge, TransFlip mutations have not been described in a somatic disease 
setting, but the combination of an inversion and translocation at a deletion breakpoint has been reported in 
recurrent translocations of renal cell carcinoma cell lines (Ali, et al. 2013). Unlike TransFlip mutations, the 
inversions described in these lines were centromeric and the genetic material distal to the breakpoint was 
deleted on the derivative chromosome (in TransFlip mutations, the distal sequence participates in a separate 
translocation event). It is of interest to note that there are a couple of reports of translocations associated 
with TSG HDs, but these studies were done at the cytogenetic level and did not report inversions (Herholz, 
et al. 2007; Misawa, et al. 2004). It is possible that these represent unidentified TransFlip mutations that 
would have been recognized if the investigators had more detailed information, such as that provided by 
WGS. 
Previous analyses of p16 deletion breakpoints found that the likely mechanism of repair was 
tissue-specific. Illegitimate V(D)J recombination was implicated in the majority of p16 deletions in 
lymphoid leukemia, while evidence of NHEJ and MMEJ were seen in lung and other non-lymphoid 
cancers (Cayuela, et al. 1997; Raschke, et al. 2005; Sasaki, et al. 2003). While microhomology was present 
at most breakpoints of both TransFlip mutations and interstitial deletions, the significance of the few bases 
involved seems insufficient to explain the mechanism, given the expected microhomology length of 1.35 
bases genome-wide by chance alone. A microhomology length of less than 7 bases is statistically 
insignificant, based on a geometric distribution and accounting for GC content. Only one junction of a 
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TransFlip mutation (the inversion half of the p16 TransFlip mutation in Pa231C) had 7 bases of 
microhomology at the junction, but the corresponding translocation half of the TransFlip mutation had only 
1 base of microhomology. No one mechanism (NHEJ, MMEJ, chromothripsis, chromoplexy, LINE-LINE-
mediated NAHR, L1 3’ transduction, or BFB cycles) explains the prevalence of complex rearrangements, 
specifically TransFlip mutations, as a mechanism of p16 and SMAD4 inactivation in our cohort.  
We propose that TransFlip mutations occur by a novel mechanism, given their unique signature 
(Table 3). It is possible that the translocation and inversion occur simultaneously to resolve breaks in the 
DNA strand, or occur sequentially (Figure 5). It remains to be determined if TransFlip mutations are the 
result of an inversion that requires a telomere (possibly via translocation) to survive (or vice versa), or if 
TransFlip mutations are a manifestation of a specific DNA repair pathway defect currently unknown. What 
is clear is that TransFlip mutations are associated with the inactivation of TSGs, not just HDs. 
It is possible that TransFlip mutations are unique to pancreatic cancer. In 2007, in their seminal 
work, Griffin and colleagues revealed the particularly high level of genomic instability in pancreatic cancer 
cell lines, which was also evident by the complex karyotypes of these distinct pancreatic cancer cell lines 
(Supplemental Table 5) (Griffin, et al. 2007). Genomic instability is a main driver of complex 
rearrangements in cancer, and often leads to the inactivation of tumor suppressor genes, including p16 and 
SMAD4, which were also recurrently lost in the cell lines reported by Griffin in 2007. Future studies should 
explore the prevalence of TransFlip mutations in other cancers, to determine if TransFlips are a 
manifestation of a pancreatic cancer specific type of genomic instability. 
Given the lack of TransFlip mutations associated with germline HDs in our cohort, we are keenly 
interested in whether TransFlip mutations underlie any human genetic disease, or whether they are 
completely unique to cancer. TransFlip mutations could be the result of an endogenous process possessed 
by all cells that are selected for in cancer because of TSG deletions. Alternatively, TransFlip mutations 
could manifest in cancer because of a fundamental defect in cancer cells, such as DNA repair, cell cycle 




Complex rearrangements like TransFlip mutations will impact PARE (personalized analysis of 
rearranged ends) analysis for early detection and minimal residual disease testing (Leary, et al. 2010). For 
monitoring minimal residual disease in a patient using PARE, it is imperative to use tumor-specific 
rearrangements that are under positive selection. TransFlip mutations are ideal PARE molecules since they 
often delete TSGs, thus providing selective advantage to the tumor cell, and have two novel junctions that 
can be assessed in the testing. One challenge of TransFlip mutations and other complex rearrangement is 
reliably detecting them from WGS data, and it remains to be seen if SV calling algorithms detect them as 
well as they do interstitial deletions, especially in primary tumors where DNA from stromal cells may 
obscure the detection of structural variants. We emphasize the utility of high density SNP microarray to 
first identify the approximate breakpoints of deletions that aid in locating the junction in WGS data. 
The most exciting implication of TransFlip mutations is that they are potentially targetable via 
synthetic lethality, similar to BRCA mutations conferring sensitivity to poly ADP ribose polymerase 
(PARP) inhibitors or by exploiting genes in the HD, like in the co-deletion of MTAP with p16 (Farmer, et 
al. 2005; Hustinx, et al. 2005). 
Our study underscores the high complexity of structural rearrangements that can occur and which 
may not be fully appreciated without the combined use of multiple techniques, including conventional 
cytogenetics, high density SNP microarray, and WGS. Further work is needed to elucidate the mechanisms 
that underlie these complex rearrangements and determine the prevalence of TransFlip mutations as a 





Figure 3.1. Signature of a HD in IGV. Shown is an interstitial deletion (0.8Mb) of p16 in Pa101C (hg19: 
chr9:21,298,029; chr9:22,123,396), visualized with IGV and the reference sequence shown above each side 
of the breakpoint. The reads upstream (A) and downstream (B) of the p16 HD are aligned, with the solid 
black line indicating the HD breakpoint. Colored bases indicate mismatched bases from reference, since 
they align to the other side of the breakpoint. Red-colored reads have an aberrant insert size with their pair, 
indicative of a HD. For this HD, there is no microhomology at the breakpoint and no non-templated bases 





Figure 3.2. Most somatic HDs are simple interstitial deletions, but TransFlip mutations more 
prevalent in p16 and SMAD4 deletions. (A) Somatic HDs were categorized as interstitial, where 
breakpoints were directly end-joined, or complex structural variants (SV). The majority (69/85) of somatic 
HDs were interstitial. The 16 complex SVs were further characterized as TransFlip mutation (translocation 
at one breakpoint and inversion at the other breakpoint, 7/16), INV (inversion at both breakpoints, 6/16), 
TRANS (inter-chromosomal translocation at both breakpoints, 2/16), or ICT (intra-chromosomal 
translocation at both breakpoints, 1/16). (B) When looking at just p16 and SMAD4 deletions, the majority 
(12/18) are complex rearrangements, and most frequently TransFlip mutations (7/18). There are no ICT 





Figure 3.3. Derivative chromosomes for p16 and SMAD4 deletions. Shown are the derivative 
chromosomes 9 (A) and 18 (B). Deletions are indicated by gap of blue chromosome material, on the short 
arm of chromosome 9 for p16 and the long arm of chromosome 18 for SMAD4. Translocations (TRANS) 
are indicated by non-blue-colored chromosome partners (all are non-recurrent), inversions (INV) are 
indicated by blue striping, point mutations (FS: frameshift, SS: splice site, MS: missense) are indicated by 
yellow starbursts. TransFlip mutations (*) underlie 3 p16 deletions (Pa222C, Pa229C, and Pa231C), and 2 
SMAD4 deletions (Pa102C and Pa227C). Simple interstitial deletions (ID) and loss of heterozygosity 





Figure 3.4. Fold-back inversion seen in one TransFlip mutation. High density SNP microarray of 18q21 
in Pa222C reveals a copy number increase (green arrow) associated with the inversion side of the TransFlip 
mutation that results in the homozygous deletion of SMAD4 (black box). This is indicative of a fold-back 





Figure 3.5. Proposed sequential mechanisms for TransFlip mutations. It is possible that the 
translocation and inversion occur simultaneously to resolve the deletion of B (boxed). Here we propose two 
stepwise mechanisms, with the TSG indicated by “B” on an example chromosome (blue). (A) An inversion 
of “BCD” (yellow) results in a DNA break and deletion of B, which is then resolved by a non-reciprocal 
translocation (red, green). (B) A DNA break between “D” and “E” (lightning bolt) is repaired by a non-




Table 3.1: Summary of p16 and SMAD4 deletions 
Gene Sample HD Size (Mb) CNV SV(s) 
p16 
Pa101C 0.8 2X†-HD-2X†  ID 
Pa102C . 3X-1X-3X ID 
Pa222C 0.1 1X-HD-1X ID+TransFlip 
Pa227C* . . . 
Pa228C 0.5 1X-HD-1X ID# 
Pa229C 4 2X†-HD-2X† TransFlip# 
Pa230C . 1X-2X INV# 
Pa231C 0.7 1X-HD-2X† TransFlip# 
SMAD4 
Pa101C . 3X-2X† INV 
Pa102C 6 1X-HD-1X TransFlip+TransFlip 
Pa222C* . . . 
Pa227C 5 2X†-HD-1X TransFlip#+TransFlip# 
Pa228C . 3X-1X to qtel INV# 
Pa229C 1.4 1X-HD-1X ID# 
Pa230C . 1X to qtel INV# 
Pa231C 0.6 1X-HD-1X ID+TRANS 
2X†=Copy-Neutral LOH, *p16 is not deleted in Pa227C and SMAD4 is not deleted in Pa222C, Dots (.) indicate that the structural or 















CDKN2A/p16 4 3 0 0 
SMAD4/DPC4 2 4 1 3 
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Table 3.3: Characteristics of TransFlip mutations 
 
Characteristics of TransFlip Mutations 
Non-recurrent breakpoints 
Not present in the germline of these PDAC patients 
Enriched at TSGs 
Inversion size ranges from 47bp to 3.4kb 
Fold-back inversions are uncommon 
Inversions can be telomeric or centromeric to the affected TSG 
Translocations are inter-chromosomal and non-reciprocal 
Non-recurrent chromosome partners in translocations 
Can occur with LOH, second TransFlip mutation, or an interstitial deletion to produce a TSG HD 




Supplemental Figure 3.1. Complexity of TransFlip in IGV. The TransFlip mutation of p16 in Pa231C 
involves a telomeric inversion (A-C) and centromeric translocation (D-F). Since the inversion is telomeric, 
it involves an additional translocation. (A-C) Here is shown the novel junctions created by the 49bp 
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inversion (hg19, chr9:21,326,868-chr9:21,326,916, red box) and translocation to chromosome 7 (hg19, 
chr7:140,023,553, blue box). The reads upstream, on chromosome 9 (A), and downstream, on chromosome 
7 (B), of the translocation are aligned. The light blue-colored reads (A) indicate that their pairs are on 
chromosome 7, while the green-colored reads (B) indicate that their pairs are on chromosome 9. There are 
2 bases of microhomology at the t(7;9) novel junction (overlap of red and blue boxes) and no non-
templated bases inserted at the junction. (C) Bidirectional Sanger sequencing confirms the novel junctions. 
(D-E) The novel junction created by the translocation (hg19, chr4:31,651,477; chr9:21,995,567), with the 
reads upstream, on chromosome 4 (D), and downstream, on chromosome 9 (E), of the translocation 
aligned. The green-colored reads (D) indicate that their pairs are on chromosome 9, while the yellow-
colored reads (E) indicate that their pairs are on chromosome 4. There is one base of microhomology at the 
breakpoint and no non-templated bases inserted at the junction. (F) Bidirectional Sanger sequencing 




Supplemental Figure 3.2. Chromothripsis in Pa102C and Pa227C. High density SNP microarray of 
chromothripsis (yellow arrows), where copy number switches between two states along the entire 
chromosome or chromosome arm. (A) Chromosome 9 exhibited chromothripsis in Pa102C. (B) 
Chromosome 18 exhibited chromothripsis in Pa102C and Pa227C. Pa101C chromosomes 9 and 18 do not 




Supplemental Table 3.1: Characteristics of known SV mechanisms 
Mechanism Characteristic(s) 
NHEJ Insertions at junction 
(non-homologous end-joining) Possibly short sequence homology 
MMEJ Microhomology (overlying or flanking) 
(microhomology-mediated end joining) Deletions 
NAHR Recurrent SVs 
(non-allelic homologous recombination) Repetitive sequence 
MEI 
Intact transposable repetitive sequence (Alu, L1) 
(mobile element insertion) 
L1 3’ transduction 
Can mimic a translocation event 
polyA sequence flanking breakpoint 
FoSTeS;MMBIR 
Multiple complex rearrangements (fork stalling and template switching; 
microhomology-mediated break-induced 
repair) 
Chromoplexy Chain of rearrangements involving multiple chromosomes in areas of active transcription and open chromatin 
Chromothripsis Switching between 2 copy number states on a chrom. 
BFB cycles Inversions and translocations; specifically fold-back inversions 
(increased copy number) (breakage-fusion-bridge) 
TransFlip mutations Translocation on one side of a deletion and inversion on the other side of the deletion 
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Pa101C 3 0 0 0 0 0 
Pa102C 11 5 2 2 1 0 
Pa222C 5 0 0 0 0 0 
Pa227C 6 1 1 0 0 0 
Pa228C 10 2 1 1 0 0 
Pa229C 14 4 2 1 0 1 
Pa230C 5 1 0 1 0 0 
Pa231C 15 3 1 1 1 0 
Total 69 16 7 6 2 1 
% of Total 81% 19% 8% 7% 2% 1% 
median HD size 
(bp)* 9,379 153,470 668,700 57,180 584,589 1,134,599 
min HD size (bp) 956 3,409 69,213 3,409 68,084 . 
max HD size (bp) 1,417,741 6,045,187 6,045,187 389,465 1,101,094 . 








Supplemental Table 3.3: Details of all somatic HDs 
Sample SV Type HD Size (bp) 
HD Coordinates 
(hg19) Genes 
Pa101C Interstitial HD 17,481 chr8:15,401,786-15,419,267 TUSC3 
Pa101C Interstitial HD 18,510 chr8:24,972,434-24,990,944 . 
Pa101C Interstitial HD 825,368 chr9:21,298,028-22,123,396 
CDKN2A/p16*, IFNA5, KLHL9, IFNA6, 
IFNA13, IFNA2, IFNA8, IFNA1, MIR31HG, 
IFNE, MIR31, MTAP, CDKN2A-AS1, 
CDKN2B, CDKN2B-AS1 
Pa102C Interstitial HD 1,126 chr6:16,884,968-16,886,094 . 
Pa102C Interstitial HD 1,633 chr3:65,117,912-65,119,545 . 
Pa102C Interstitial HD 5,710 chr3:98,943,806-98,949,516 . 
Pa102C Interstitial HD 6,959 chr8:40,182,856-40,189,815 . 
Pa102C Interstitial HD 8,157 chr6:19,041,219-19,049,376 . 
Pa102C Interstitial HD 9,746 chr8:15,777,416-15,787,162 . 
Pa102C Interstitial HD 11,828 chr3:53,027,071-53,038,899 
SFMBT1, RFT1, PRKCD, TKT, DCP1A, 
Y_RNA, SNORA26 
Pa102C Interstitial HD 18,510 chr8:24,972,434-24,990,944 . 
Pa102C Interstitial HD 48,304 chr5:97,047,855-97,096,159 . 
Pa102C Interstitial HD 54,259 chr5:180,376,278-180,430,537 BTNL3, BTNL8 
Pa102C Interstitial HD 155,155 chr8:39,232,074-39,387,229 ADAM5P, ADAM3A 
Pa102C INV+INV 92,568 chr11:55,365,428-55,457,996 OR4C11, OR4P4, OR4S2 
Pa102C INV+INV 389,465 chr18:75,924,436-76,313,901 . 
Pa102C TRANS+ TRANS 68,084 
chr9:84,607,953-
84,676,037 FAM75D1 
Pa102C TransFlip 69,213 chr1:248,741,764-248,810,977 OR2T10, OR2T11 
Pa102C TransFlip 6,045,187 chr18:47,999,471-54,044,658 
SMAD4#, MAPK4, MRO, ME2, ELAC1, 
MEX3C, LOC100287225, DCC, 
LOC102724651, LOC101928167, MBD2, 
SNORA37, POLI, STARD6, C18orf54, 
DYNAP, RAB27B, CCDC68, 
LOC101927229, TCF4, MIR4529, 
LOC101927273, LINC01539 
Pa222C Interstitial HD 1,005 chr3:61,127,189-61,128,194 FHIT 
Pa222C Interstitial HD 9,752 chr4:10,392,430-10,402,182 . 
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Pa222C Interstitial HD 10,837 chr12:59,935,796-59,946,633 . 
Pa222C Interstitial HD 34,123 chr8:83,740,865-83,774,988 . 
Pa222C Interstitial HD 97,053 chr9:21,977,376-22,074,429 CDKN2A/p16*, CDKN2B, CDKN2B-AS1 
Pa227C Interstitial HD 3,794 chr6:8,337,733-8,341,527 . 
Pa227C Interstitial HD 6,332 chr6:141,751,266-141,757,598 . 
Pa227C Interstitial HD 8,488 chr8:104,271,982-104,280,470 LOC100499183 
Pa227C Interstitial HD 9,441 chr14:35,605,628-35,615,069 KIAA0391 
Pa227C Interstitial HD 12,776 chr17:54,160,182-54,172,958 . 
Pa227C Interstitial HD 18,510 chr8:24,972,434-24,990,944 . 
Pa227C TransFlip 5,001,960 chr18:48,463,089-53,465,049 
SMAD4#, ME2, ELAC1, MEX3C, 
LOC100287225, DCC, LOC102724651, 
LOC101928167, MBD2, SNORA37, POLI, 
STARD6, C18orf54, DYNAP, RAB27B, 
CCDC68, LOC101927229, TCF4, MIR452 
Pa228C Interstitial HD 956 chr6:74,832,504-74,833,460 AF086303 
Pa228C Interstitial HD 2,442 chr6:24,325,366-24,327,808 DCDC2 
Pa228C Interstitial HD 3,667 chr18:73,862,188-73,865,855 . 
Pa228C Interstitial HD 3,746 chr2:195,363,696-195,367,442 . 
Pa228C Interstitial HD 4,606 chr18:51,205,969-51,210,575 . 
Pa228C Interstitial HD 6,113 chr17:56,207,497-56,213,610 . 
Pa228C Interstitial HD 6,131 chr17:70,815,230-70,821,361 SLC39A11 
Pa228C Interstitial HD 6,465 chr7:110,181,968-110,188,433 . 
Pa228C Interstitial HD 7,652 chr6:48,930,882-48,938,534 . 
Pa228C Interstitial HD 485,050 chr9:21,950,541-22,435,591 CDKN2A/p16*, CDKN2B, CDKN2B-AS1 
Pa228C INV+INV 21,791 chr9:22,720,074-22,741,865 FLJ35282 
Pa228C TransFlip 205,910 chr9:6,650,981-6,856,891 KDM4C, DQ580140 
Pa229C ICT+ICT 1,134,599 chr17:63,527,925-64,662,524 AXIN2, CEP112, APOH, PRKCA 
Pa229C Interstitial HD 1,007 chr8:17,580,760-17,581,767 MTUS1 
Pa229C Interstitial HD 3,634 chr4:152,990,313-152,993,947 . 
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Pa229C Interstitial HD 4,625 chr18:63,907,136-63,911,761 . 
Pa229C Interstitial HD 4,759 chr5:111,939,582-111,944,341 . 
Pa229C Interstitial HD 4,904 chr4:112,237,509-112,242,413 . 
Pa229C Interstitial HD 6,107 chr1:62,113,414-62,119,521 . 
Pa229C Interstitial HD 6,957 chr18:50,242,911-50,249,868 DCC 
Pa229C Interstitial HD 6,959 chr8:40,182,856-40,189,815 . 
Pa229C Interstitial HD 8,527 chr18:63,723,838-63,732,365 . 
Pa229C Interstitial HD 9,379 chr22:30,044,155-30,053,534 NF2 
Pa229C Interstitial HD 15,381 chr18:50,014,115-50,029,496 DCC 
Pa229C Interstitial HD 19,143 chr4:189,248,699-189,267,842 . 
Pa229C Interstitial HD 24,080 chr13:69,244,702-69,268,782 . 
Pa229C Interstitial HD 1,417,741 chr18:48,434,141-49,851,882 
SMAD4#, ME2, ELAC1, MEX3C, 
LOC100287225 
Pa229C INV+INV 10,274 chr4:116,166,907-116,177,181 . 
Pa229C TransFlip 87,849 chr22:36,250,342-36,338,191 RBFOX2 
Pa229C TransFlip 3,975,324 chr9:20,345,146-24,320,470 
CDKN2A/p16*, MLLT3, MIR4473, 
MIR4474, FOCAD, FOCAD-AS1, MIR491, 
PTPLAD2, IFNB1, IFNW1, IFNA21, IFNA4, 
IFNA7, IFNA10, IFNA16, IFNA17, IFNA14, 
IFNA22P, IFNA5, KLHL9, IFNA6, IFNA13, 
IFNA2, IFNA8, IFNA1, MIR31HG, IFNE, 
MIR31, MTAP, CDKN2A-AS1, CDKN2B, 
CDKN2B-AS1, DMRTA1, LINC01239, 
LOC101929563, ELAVL2 
Pa230C Interstitial HD 4,478 chr3:6,650,160-6,654,638 AF279782 
Pa230C Interstitial HD 4,618 chr3:11,410,124-11,414,742 ATG7 
Pa230C Interstitial HD 4,886 chr6:132,707,536-132,712,422 MOXD1 
Pa230C Interstitial HD 10,138 chr9:6,700,475-6,710,613 . 
Pa230C Interstitial HD 31,893 chr13:24,631,706-24,663,599 SPATA13 
Pa230C INV+INV 3,409 chr11:97,517,721-97,521,130 . 
Pa231C Interstitial HD 2,340 chr9:79,555,762-79,558,102 . 
Pa231C Interstitial HD 5,146 chr6:77,097,496-77,102,642 . 
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Pa231C Interstitial HD 5,318 chr7:159,117,444-159,122,762 . 
Pa231C Interstitial HD 7,898 chr4:41,969,874-41,977,772 . 
Pa231C Interstitial HD 9,858 chr6:81,283,720-81,293,578 . 
Pa231C Interstitial HD 10,600 chr3:12,904,010-12,914,610 DQ587889, DQ587809 
Pa231C Interstitial HD 17,028 chr9:24,502,071-24,519,099 . 
Pa231C Interstitial HD 20,055 chr4:64,694,328-64,714,383 . 
Pa231C Interstitial HD 21,792 chr6:77,437,256-77,459,048 . 
Pa231C Interstitial HD 64,781 chr8:123,562,465-123,627,246 . 
Pa231C Interstitial HD 107,148 chr8:138,259,213-138,366,361 . 
Pa231C Interstitial HD 134,333 chr6:91,985,925-92,120,258 . 
Pa231C Interstitial HD 498,258 chr4:178,588,820-179,087,078 AK094945, LOC285501 
Pa231C Interstitial HD 567,944 chr3:69,892,576-70,460,520 MITF, BC015590 
Pa231C Interstitial HD 621,563 chr18:48,570,319-49,191,882 SMAD4
#, MEX3C, LOC100287225 
Pa231C INV+INV 101,030 chr12:28,931,318-29,032,348 . 
Pa231C TRANS+TRANS 1,101,094 
chr17:11,169,977-
12,271,071 
SHISA6, DNAH9, ZNF18, MAP2K4, 
MIR744, U11 
Pa231C TransFlip 668,700 chr9:21,326,867-21,995,567 
CDKN2A/p16*, KLHL9, IFNA6, IFNA13, 
IFNA2, IFNA8, IFNA1, MIR31HG, IFNE, 
MIR31, MTAP, CDKN2A-AS1, CDKN2B, 
CDKN2B-AS1 











Underlying SV for 1st 
Del Underlying SV for 2
nd Del  
(producing 1X/LOH) (producing HD) 
p16 
Pa101C 0.8 2X†-HD-2X†  CN-LOH (chr9 is 2X†) Interstitial Deletion 
Pa102C . 3X-1X-3X Interstitial Deletion                (chr9 is 3X) . 
Pa222C 0.1 1X-HD-1X 




Pa228C 0.5 1X-HD-1X LOH (9p is 1X) Interstitial Deletion 
Pa229C 4 2X†-HD-2X† CN-LOH (chr9 is 2X†) 
t(9;22)(p21.3;q12.3) 
3,373bp INV with t(9;22) 
(p21.3;q12.3) 
Pa230C . 1X-2X INV . 
Pa231C 0.7 1X-HD-2X† LOH  (1X from HD to 9ptel) 
INV with t(7;9)(q34;p21.3)  
t(4;9)(p15.1;p21.3)x2 
SMAD4 
Pa101C . 3X-2X† 28.5Mb INV . 
Pa102C 6 1X-HD-1X 
t(14;18)(q21.2;q21.1) 
INV to repetitive 
region 
t(2;18)(q36.1;q21.1) 
35Mb INV to centromere 
Pa227C 5 2X†-HD-1X 





Pa228C . 3X-1X to qtel 264bp INV . 
Pa229C 1.4 1X-HD-1X 
1X to centromere, where 
becomes 3X to 18ptel 
1X to 18qtel 
Interstitial Deletion 
Pa230C . 1X to qtel 53bp INV . 
Pa231C 0.6 1X-HD-1X t(5;18)(p14.3;q11.2) 
1X to 18qtel 
Interstitial Deletion 
Homozygous deletion (HD), copy number variant (CNV), structural variant (SV), loss of heterozygosity (LOH; 1X), deletion (Del), 
copy-neutral LOH (CN-LOH; 2X†), inversion (INV), 
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Supplemental Table 3.6: Breakpoint characteristics of p16 and SMAD4 deletions 
Gene Sample SV 
Potential Mechanism 





















Pa101C ID 0 0 L1PA4 (L); L1MA5A (R) N N N . 
Pa102C ID 0 1 MERV50-int (L); L1M3c (R) N N Y . 
Pa222C 
INV with 
TRANS 0/0 4/1 
L1ME3A 
(INV); L2a (3) N/N ROBO1 (3) 
N 
N 





TRANS 0 1 L1MEf (10); MSTB-int (9) N N N 
Pa228C ID 0 2 AluSp (L); HERV9-int (R) N MTAP (L) N . 
Pa229C 
TRANS 0 1 N N MLLT3 (L) 
N 
Y 
INV 0 2 MSTB-int (L) N N . 
Pa230C 
INV-1 0 0 N N 
N N . 
INV-2 0 3 LTR1D (R) N 
Pa231C 
INV with 
TRANS 0/0 1/7 L1MB8 (7) N/N KLHL9 (9) N 
N 
TRANS 0 1 MER58B (4) N MTAP (9) Y 
SMAD
4 
Pa101C INV 0 0 L2c (L) N RPRD1A (L) N . 
Pa102C 







INV ? ? ? ? ? . 
TRANS 0 0 MSTD (2) N N N 
INV 1 1 L1MC4a (R) N N . 
Pa227C 
fold-back 
INV 0 1 
AluJr4 (L); 
L1MEg (R) N ME2 (L&R) 
Y 
. 
TRANS 0 3 L1MEc (18) N NKAIN2 (6) N 
INV ? ? ? ? ? . 
TRANS 0 0 L1M3 (18) N ADAM11 (17) N 
Pa228C INV 0 1 L3 (L&R) N N N . 
Pa229C ID 0 0 L1M5 (L); AluSp (R) N ME2 (L) N . 
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Pa230C INV 0 1 N N N N . 
Pa231C 
ID 0 0 L2b (R) N SMAD4 (L) 
N 
. 
TRANS 0 3 TcMar-Tigger (18) N 
TAF4B (18); 
CDH12 (5) Y 
Interstitial deletion (ID), inversion (INV), translocation (TRANS), left breakpoint (L), right breakpoint (R), chromosome number (#), 
microhomology (MH), non-homologous end-joining (NHEJ), microhomology end-joining (MHEJ), mobile element insertion (MEI), 


















Challenges in discovering familial pancreatic cancer predisposition 




 Pancreatic ductal adenocarcinoma (PDAC) is a nearly uniformly lethal disease, where up 
to 10% of the cases occurring in familial aggregates. The genes underlying the majority (>80%) 
of these familial pancreatic cancer (FPC) cases are unknown. Previous whole exome sequencing 
(WES) strategies have successfully identified FPC predisposition genes PALB2 and ATM, which 
allows for the identification of at-risk individuals for which early detection resources can be 
focused on. In this study, we have employed an integrative strategy of high density SNP 







Over 48,000 cases of pancreatic ductal adenocarcinoma (PDAC) are expected to be 
diagnosed in the U.S. in 2015, and nearly 5,000 will occur in familial aggregate (familial 
pancreatic cancer, FPC) (92). FPC is defined as a pancreatic cancer in a patient with at least one 
first-degree relative with pancreatic cancer (i.e. 2 or more affected first-degree relatives). A 
challenge in early detection efforts for FPC is identifying at-risk individuals since the vast 
majority of FPC kindreds have an unidentified predisposition gene. Currently known FPC 
predisposition genes, identified by traditional linkage mapping and more recently, next generation 
sequencing, account for less than 20% of FPC cases (see Table 1.1). Recent efforts have 
highlighted the success of sequencing studies to identify new FPC predisposition genes, with 
PALB2 and ATM discovered using whole exome sequencing (WES) of the tumor and matched 
normal for FPC patients (17, 93).  
Most cancer predisposition genes act as tumor suppressors (TSGs) with biallelic 
inactivating alterations, following the two hit hypothesis first described by Nicholls in 1969 and 
popularized by Knudson (26, 27).  In the two hit model for inherited cancer, the first hit 
(mutation) in the TSG is inherited and the second hit in the same TSG is acquired somatically by 
chance. Whereas oncogenes are most commonly mutated at recurrent same amino acid positions 
(“hotspots”), TSGs are mutated through protein truncating mutations that occur most often 
throughout the length of the protein (94).  
Here, we build upon the successful strategy employed to identify the PALB2 and ATM 
genes. We used an integrated approach including high density SNP microarrays, exomic 
sequencing (WES), whole genome sequencing (WGS), and RNA-sequencing (RNA-Seq) to 
identify new candidate FPC predisposition genes. The majority of our screening was performed 
under the assumption that our FPC gene would conform to the classic two-hit hypothesis. 
66 
 
Materials and Methods 
Study Participants 
This study was reviewed and approved by the Institutional Review Board at Johns 
Hopkins Medical Institutions, and informed consent was obtained from all study participants. 
Cancer cell lines were generated from the tumors of patients with FPC, obtained from resection 
surgery or rapid autopsy, and generated by direct culture or xenograft, as previously described 
(68). Cell lines were karyotyped using a previously described method (69). Matched normal DNA 
was obtained from either frozen tissue or Epstein-Barr virus (EBV)-transformed lymphoblasts. 
Preparation of Genomic DNA and RNA 
Genomic DNA was extracted from early passage cell lines and matched normal using 
QIAamp DNA mini kit (Qiagen, Valencia, CA), per manufacturer’s instruction. All cell lines 
were verified by STR analysis using the ABI Profiler kit (Life Technologies, Carlsbad, CA) on 
the 3130xL Genetic Analyzer instrument (Life Technologies).  RNA was extracted from cell lines 
using RNeasy mini kit (Qiagen), per manufacturer’s instruction.  A HPDE (human pancreatic 
ductal epithelium) cell line was used as a normal control for RNA-Seq. 
High Density SNP Microarray 
The Omni2.5 array (Illumina, San Diego, CA) was used to analyze cancer cell lines and 
matched normal samples at 2,379,855 (2.5M) SNP loci (one SNP every ~1,000bp).  
GenomeStudio (Illumina) was used to identify copy number variants (CNVs) using the following 
criteria: an average LogR Ratio (LRR) ≤ -2.0 for homozygous deletions; LRR of 0-0.53 and B 
Allele Frequency (BAF) of 0 or 1 for loss of heterozygosity (LOH); and an average LRR ≥ 1.4, 
with at least 1 SNP LRR ≥ 2.0, for amplifications. A minimum of 4 SNPswere required for the 
region to be called an alteration, with the boundaries being the first and last SNPs that meet 
criteria, and adjacent regions (within 100kb) were considered to be one alteration. KaryoStudio 
(Illumina) was used to visually confirm CNVs. 
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Whole exome and whole genome sequencing 
For whole exome sequencing, genomic DNA libraries prepared with Agilent's SureSelect 
Paired-End Version 2.0 Human Exome Kit (Agilent, Santa Clara, CA) were paired-end 
sequenced (2x75bp) on a GAIIx Genome Analyzer (Illumina) to 200X coverage (68).  For whole 
genome sequencing, genomic DNA was paired-end sequenced (2x100bp) on a HiSeq 2000 
(Illumina) to a 60X coverage for cancers and 30X coverage for matched normal by Personal 
Genome Diagnostics (Baltimore, MD). For both WES and WGS, the resulting reads were aligned 
to human genome (hg19) with Eland v.2 algorithm in CASAVA 1.7 software (Illumina). 
RNA-Seq 
Using TruSeq Stranded Total RNA Sample Preparation (Illumina), cDNA libraries were 
prepared from ribosomalRNA-depleted Total RNA and paired-end sequenced (2x100bp) on a 
HiSeq 2000 to a level of 50M reads. RSEM was used to align the sequences to human genome 
(hg19) (31).  Alterations were visually confirmed using IGV. 
Variant Filtering 
Since we were looking for TSGs, we specifically looked for private truncating variants 
(PTVs), which include copy number deletions, frameshifting insertions and deletions, stop gain 
mutations, stop loss mutations, missense mutations of the first amino acid, and splice site 
mutations in positions -1, -2, +1, or +2 that are not common in the general population (<1% 
minor allele frequency, MAF). We annotated mutations using ANNOVAR (60), to include 
information about MAF, predicted effect on protein (PolyPhen, SIFT), and conservation 
(phastConsElements 46-way).   
Our strategy looked for genes with both an alteration in cancer cell line (somatic hit) and 
an alteration in the matched normal sample (germline hit). The hits could be large inactivating 
alterations (e.g. deletions) or small inactivating alterations (e.g. point mutations). Candidate 
mutations were first visually confirmed using Integrated Genomics Viewer (IGV) (Broad 
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Institute, Boston, MA) and then experimentally confirmed by PCR amplification and 






In this chapter, we carried out high density SNP microarray (probes every ~1,000 bases), 
WES, WGS, RNA-Seq, and conventional karyotyping (Figure 1). We looked for deletions by 
SNP microarray; for point mutations by WES and WGS, and for loss of expression by RNA-Seq. 
The methods also served to cross-confirm mutations or deletions discovered. Bidirectional Sanger 
sequencing was used to confirm candidate mutations and deletions.  
Germline intragenic HDs in Both FPC and Normal Controls 
We first investigated whether the FPC patients might carry HDs in predisposition genes. 
The number of germline intragenic HDs in FPC samples were not statistically increased from 
normal controls (Figure 2, Table 2) (median 5 vs 4, p=0.20 by unpaired two-tailed t-test), and the 
amount of genetic material deleted in our FPC samples was also not statistically increased from 
normal controls (median 68kb vs 90kb, p=0.64 by unpaired two-tailed t-test). The locus including 
ADAM5P and ADAM3A was recurrently deleted in the germline of FPC patients (PA228, PA229, 
and PA231). However, analysis of normal controls showed this specific HD is common in the 
general population, and thus likely benign. All germline deletions were simple interstitial 
deletion, with the exception of a recurrent extragenic deletion with an inversion at each 
breakpoint.  
No Candidate Genes Identified by Germline PTV Analysis 
No clearly deleterious mutations were identified in ATM, STK11, PRSS1, PALB2, 
BRCA2, or SPINK1. No loss of expression was seen in the genes either. We looked for genes with 
a germline defect in combination with a somatic defect (“2nd hit”). The resulting hits from these 
either did not confirm (e.g. CDC27, result of pseudogenes) or were found to be common (and 
thus likely benign) variants by exome variant server (ESP6500) and 1000 Genomes databases 
(MAF>1%). Since DNA damage repair genes account for the majority of known FPC 
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predisposition genes, we extended our search to missense mutations with MAF<1% and predicted 
to be deleterious by both PolyPhen and SIFT, but still had no genes with biallelic inactivation, 
where one defect was in the germline. Possible dominant negative candidate genes with 
suggestive 1st hits, but lack of an obvious 2nd hit, include STK11IP (Pa229C) and RBBP8 






 Here we have characterized a cohort of 8 FPC patients using an integration of 
chromosome-level, DNA-level, and RNA-level analyses. Despite our detailed analysis and 
follow-up testing of many putative genes, we have no bona fide candidate gene for FPC 
predisposition. Our research does highlight that normal germlines have homozygous deletions of 
genes, like ADAM5P and ADAM3A. It remains to be seen if there is any biological consequence 
for these deletions.  
 Current analysis efforts are focused on RNA-Seq level variation, including allele-specific 
expression (ASE), which may indicate epigenetic silencing of the second allele (2nd hit), and 
differential gene expression between our FPC cohort and a sporadic PDAC cohort. The possible 
role of alternate or aberrant splicing is also being explored. 
 Future work could add proteomics and epigenetics analyses of this cohort of FPC lines. 
However that still does not guarantee the identification of a predisposition gene. Instead, we 
investigators need to explore novel mechanisms of cancer predisposition, beyond biallelic 
inactivation of a gene by intragenic mutations. Future analysis should explore (1) monoallelic 
inactivation, such as haploinsufficiency and dominant negative mechanisms, and (2) intergenic or 
non-coding mutations that may produce dysregulated gene expression.  
 It is possible that these FPC kindreds of our cohort do carry an inherited defect that 
predisposes to PDAC, but the specific case in each kindred that we have studied does not carry 
the inherited defect and are just coincidental sporadic PDAC cases in FPC kindreds, the definition 





Figure 4.1. Integrative approach towards identifying new FPC predisposition genes. We 
have employed an integrated approach of analysis at the levels of chromosome (conventional 









Figure 4.2. Germline intragenic HDs in normal and FPC cohorts. Normal samples include 23 




Table 4.1. Value of an integrated approach  
Alteration Karyotype SNP Microarray WES WGS RNA-Seq 
CN-LOH  X +/- +/- +/- 
Reciprocal 
Translocation X  +/- X +/- 
Inversion +/-   X +/- 
Large Deletion +/- X +/- X  
Deleterious Intragenic 
Mutation   X X X 
Small Intragenic 
Deletion  +/- +/- X X 
Aberrant Splicing     X 
Epigenetic Silencing 
(e.g. methylation)         X 
X=should detect; +/-=may or may not detect, copy-neutral loss of heterozygosity (CN-LOH), whole exome sequencing (WES), whole 















Sample #HDs Total DNA Deleted (bp) 
Pa101N 4 22,903 
Pa102N 4 20,368 
Pa222N 5 64,252 
Pa227N 7 66,552 
Pa228N 5 178,822 
Pa229N 3 246,738 
Pa230N 7 69,076 
Pa231N 6 269,578 
FPC_Med 5 67,814 
FPC_Avg 5.1 117,286 
CIDR_06985 5 180,569 
CIDR_07048 5 95,579 
CIDR_10846 8 557,405 
CIDR_10847 2 48,940 
CIDR_10851 4 69,217 
CIDR_10860 3 84,972 
CIDR_10861 4 745,759 
CIDR_11881 6 93,058 
CIDR_11882 5 30,607 
CIDR_11992 5 242,264 
CIDR_11993 4 89,731 
CIDR_11994 4 95,599 
CIDR_11995 3 9,963 
CIDR_12056 2 31,184 
CIDR_12057 7 123,722 
CIDR_12144 5 166,924 
CIDR_12145 3 13,823 
CIDR_12146 5 24,063 
CIDR_12155 2 76,359 
CIDR_12156 4 194,081 
CIDR_12239 5 184,298 
CIDR_18501 2 7,930 
CIDR_18859 6 84,293 
CIDR_Med 4 89,731 
CIDR_Avg 4.3 141,319 
p-value                                    















Biological Basis for the Similar Age of Onset in Familial and Sporadic PDAC (Chapter 2) 
We have shown that FPC and sporadic PDAC have a similar age of onset. It remains a 
conundrum in the field as to how one can inherit a predisposition to cancer without accelerating 
the age of onset. We propose that it is a combination of shared driver genes and a pancreatic 
tissue-specific effect. This hypothesis represents an important area for future study as it may shed 
light on PDAC carcinogenesis in general. Is there a “5th gene”, such as a “gatekeeper” gene that is 
age-independent but increases the frequency or likelihood of developing PDAC, such as immune 
dysfunction, known to decrease with age? 
Elucidation of TransFlip Prevalence and Mechanism of Production (Chapter 3) 
We have discovered a new mechanism of TSG inactivation, TransFlip mutations. In FPC, 
TSGs are more commonly deleted by TransFlip mutations than simple interstitial deletions. 
TransFlip mutations were also found in sporadic PDAC, and it remains to be seen what the 
prevalence of TransFlip mutations are across all cancers, and that knowledge may give insight to 
the mechanism that gives rise to TransFlip mutations. Are TransFlip mutations ever the cause of 
an inherited human genetic disease? Are TransFlip mutations the manifestation of a specific DNA 
repair defect? If so, then TransFlip mutations may confer sensitivity to drugs that inhibit parallel 
pathways, in a synthetic lethality mechanism similar to BRCA2 mutations and PARP inhibitors.  
Identification of All Genes that Predispose to FPC (Chapter 4) 
Our effort toward identifying new FPC predisposition genes highlights the challenge of 
such an endeavor. Major challenges of filter-based gene identification are (1) underlying genetic 
heterogeneity of FPC, (2) many putative deleterious mutations and even homozygous deletions 
are common variants, seen in the germline of normal individuals, making it hard to distinguish 
tumorigenic mutations from benign or tolerated mutations in a background of 1000s of germline 
mutations in a given sample, and (3) phenocopies, where patients in a family with FPC do not 
carry the genetic predisposition, but instead are a sporadic PDAC case.  
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An additional challenge is that yet-discovered predisposition genes may promote 
tumorigenesis in ways that are atypical. This includes haploinsufficiency, dominant negative 
mutations, and intergenic (non-coding) mutations that disrupt gene regulation. It remains to be 
seen if the lack of an obvious candidate predisposition gene is due to (1) the methods employed in 
our study are unable to detect the mechanism of gene inactivation (e.g. a post-translational 
modification that would require proteomics analysis), (2) inadequate tools to analyze the data 
(e.g. annotation issues that may preclude identification of coding mutations), or (3) shortcomings 
of knowledge of the human genome complexity (e.g. regulatory regions that are not currently 
annotated). While our analysis focused on intragenic mutations in protein-coding genes, as the 
understanding of the human genome improves, our current data can be re-analyzed for newly 
identified regulatory mutations in non-coding regions and expression levels of non-coding RNAs. 
Impact on Cancer Patients 
In summary, our results indicate the similarity of FPC to its sporadic counterpart, with 
respect to age of onset and genetic characteristics. This highlights the utility of early detection 
efforts tested in familial cohorts to the larger population. However, early detection testing that 
utilizes PARE will require more sensitive and specific SV calling algorithms.  
We have discovered a new class of SV, TransFlip mutations, which are present in both 
familial and sporadic PDAC. The lack of TransFlip mutations in the germline suggests that they 
are completely unique to cancer. The most exciting implication of TransFlip mutations is that 
they are potentially targetable via synthetic lethality, similar to BRCA mutations conferring 
sensitivity to poly ADP ribose polymerase (PARP) inhibitors or by exploiting genes in the HD, 
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